On April 15, 2024, Shah Capital Management, Inc announced that it has been deeply disappointed in Novavax performance and the failure of its leadership to realize shareholder value reflective of the Company?s significant competitive advantages and sizeable market opportunity. Shah Capital added that recognizing this pressing need for the Company to offer the investment community a more proactive and innovative strategy, it is recommending the appointment to the board of 2 new independent directors: Suresh Katta, Venkat Peri who possess the necessary experience to tackle the underperformance of the business which will improve its share price.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.29 USD | +4.89% | +5.41% | -10.62% |
Apr. 15 | Sector Update: Health Care Stocks Gain Monday Afternoon | MT |
Apr. 15 | Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.62% | 572M | |
+1.77% | 42.75B | |
+47.70% | 41.61B | |
+12.24% | 41.34B | |
-8.83% | 26.59B | |
+7.44% | 25.49B | |
-23.01% | 18.12B | |
+30.56% | 12.24B | |
-1.82% | 11.76B | |
+8.35% | 11B |
- Stock Market
- Equities
- NVAX Stock
- News Novavax, Inc.
- Shah Capital Nominates Director Candidates for Novavax